drugset / Trial / NCT00685464

Intravenous Versus Intracoronary Use of Abciximab

NCT00685464

RandomizedFactorialOpen-labelTreatment

Summary

The aim of this study is to investigate wether intracoronary use of bolus Abciximab is superior to intravenous bolus in patients undergoing percutaneous coronary intervention.

Timeline

Start
2006-01
Primary completion
2008-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abciximab Monoclonal antibody 0.125 ug/kg Intravenous